Fintel reports that on May 14, 2025, Maxim Group downgraded their outlook for Cellectar Biosciences (NasdaqCM:CLRB) from Buy ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode ...

James Caruso; President, Chief Executive Officer, Director; Cellectar Biosciences Inc. Chad Kolean; Chief Financ ...

Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom ...

Analysts are estimating that Cellectar Biosciences will report an earnings per share (EPS) of $-0.16. Anticipation surrounds ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2025 Earnings Call Transcript May 8, 2025 Arcadia Biosciences, Inc. beats earnings expectations. Reported EPS is $1.9, expectations were $-0.98.

The consensus rating for Harvard Bioscience is Outperform. Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable ...

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago.

Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs). Avidity is revolutionizing ...

Skye Bioscience Inc. (SKYE) reported its financial results for the first quarter of 2025, highlighting a significant increase in research and development (R&D) expenses as the company advances its ...

DALLAS (AP) — DALLAS (AP) — Arcadia Biosciences Inc. (RKDA) on Thursday reported earnings of $2.6 million in its first quarter. On a per-share basis, the Dallas-based company said it had ...

FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization ...